Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 499

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women

Open access
Wells, George A, Cranney, Ann, Peterson, Joan, Boucher, Michel, Shea, Beverley, Welch, Vivian, Coyle, Doug, Tugwell, Peter·2008·Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.cd003376.pub3
Open this paper in CoChat — free account

Abstract

BACKGROUND: Osteoporosis is an abnormal reduction in bone mass and bone deterioration leading to increased fracture risk. Risedronate belongs to the bisphosphonate class of drugs which act to inhibit bone resorption by interfering with the activity of osteoclasts. OBJECTIVES: To assess the efficacy of residronate in the primary and secondary prevention of osteoporotic fractures in postmenopausal women. SEARCH STRATEGY: We searched CENTRAL, MEDLINE and EMBASE. Relevant randomized controlled trials published between 1966 to 2007 were identified. SELECTION CRITERIA: Women receiving at least one year of risedronate for postmenopausal osteoporosis were compared to those receiving placebo or concurrent calcium/vitamin D or both. The outcome was fracture incidence. DATA COLLECTION AND ANALYSIS: We carried out study selection and data abstraction in duplicate. Study quality was assessed through the reporting of allocation concealment, blinding and withdrawals. Meta-analysis was preformed using relative risks and a >15% relative change was considered clinically important. MAIN RESULTS: Seven trials were included in the review representing 14,049 women. Relative (RRR) and absolute (ARR) risk reductions for the 5 mg dose were as follows. Risk estimates for primary prevention were available only for vertebral and non vertebral fractures and showed no statistically significant effect of risedronate on fractures. For secondary prevention, a significant 39% RRR in vertebral fractures (RR 0.61, 95% CI 0.50 to 0.76) with 5% ARR was found. For non-vertebral fractures, a significant 20% RRR (RR 0.80, 95% CI 0.72 to 0.90) with 2% ARR and for hip fractures there was a significant 26% RRR (RR: 0.74, 95% CI 0.59 to 0.94) with a 1% ARR. When primary and secondary prevention studies were combined, the reduction in fractures remained statistically significant for both vertebral (RR 0.63, 0.51 to 0.77) and non vertebral fractures (RR 0.80, 0.72 to 0.90)For adverse events, no statistically significant differences were found in any of the included studies. However, observational data has led to concerns regarding the potential risk for upper gastrointestinal injury and, less commonly, osteonecrosis of the jaw. AUTHORS' CONCLUSIONS: At 5 mg/day a statistically significant and clinically important benefit in the secondary prevention of vertebral, non-vertebral and hip fractures was observed, but not for wrist. The level of evidence for secondary prevention is Gold (www.cochranemsk.org) for vertebral and non-vertebral and Silver for hip and wrist. There were no statistically significant reductions in the primary prevention of vertebral and non-vertebral fractures. The level of evidence is Silver.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd003376.pub3

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 75

  1. Herd, 1997, The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study, American Journal of Medicine, 103, 92, 10.1016/S0002-9343(97)00019-3 · DOI
  2. Ishida, 2004, Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study, American Journal of Medicine, 117, 549, 10.1016/j.amjmed.2004.05.019 · DOI
  3. Lyritis, 1997, The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study, Clinical Rheumatology, 16, 354, 10.1007/BF02242451 · DOI
  4. Meunier, 1997, Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up) [see comment] [erratum appears in J Clin Endocrinol Metab 1997 Nov;82(11):3740], Journal of Clinical Endocrinology and Metabolism, 82, 2784
  5. Montessori, 1997, The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment, Osteoporosis International, 7, 52, 10.1007/BF01623461 · DOI
  6. Pacifici, 1988, Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study, Journal of Clinical Endocrinology and Metabolism, 66, 747, 10.1210/jcem-66-4-747 · DOI
  7. Pouilles, 1997, Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy, Osteoporosis International, 7, 213, 10.1007/BF01622291 · DOI
  8. Shiota, 2001, Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis, Journal of Orthopaedic Science, 6, 133, 10.1007/s007760100060 · DOI
  9. Storm, 1990, Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis [see comment], New England Journal of Medicine, 322, 1265, 10.1056/NEJM199005033221803 · DOI · Paper page
  10. Watts, 1990, Intermittent cyclical etidronate treatment of postmenopausal osteoporosis [see comment], New England Journal of Medicine, 323, 73, 10.1056/NEJM199007123230201 · DOI · Paper page
  11. Watts, 1990, Intermittent cyclical etidronate treatment of postmenopausal osteoporosis [see comment], New England Journal of Medicine, 323, 73, 10.1056/NEJM199007123230201 · DOI · Paper page
  12. Watts, 1990, Intermittent cyclical etidronate treatment of postmenopausal osteoporosis [see comment], New England Journal of Medicine, 323, 73, 10.1056/NEJM199007123230201 · DOI · Paper page
  13. Wimalawansa, 1998, A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis, American Journal of Medicine, 104, 219, 10.1016/S0002-9343(98)00029-1 · DOI
  14. Adami, 2000, Prevention of early postmenopausal bone loss with cyclical etidronate, Journal of Endocrinological Investigation, 23, 310, 10.1007/BF03343728 · DOI
  15. Anderson, 1984, Preliminary observations of a form of coherence therapy for osteoporosis, Calcified Tissue International, 36, 341, 10.1007/BF02405341 · DOI
  16. Bolanca, 1998, Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women, Acta Medica Croatica, 52, 159
  17. Chilibeck, 2002, The effect of strength training combined with bisphosphonate (etidronate) therapy on bone mineral, lean tissue, and fat mass in postmenopausal women, Canadian Journal of Physiology and Pharmacology, 80, 941, 10.1139/y02-126 · DOI
  18. Cortet, 2001, Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy, Joint, Bone, Spine: Revue du Rhumatisme, 68, 410, 10.1016/S1297-319X(01)00297-4 · DOI
  19. Evans, 1993, The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women, Osteoporosis International, 3, 71, 10.1007/BF01623376 · DOI
  20. Guanabens, 2000, Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial, Bone, 27, 123, 10.1016/S8756-3282(00)00303-3 · DOI
  21. Gurlek, 1997, Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study, Calcified Tissue International, 61, 39, 10.1007/s002239900291 · DOI
  22. Harris, 1993, Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy [see comment], American Journal of Medicine, 95, 557, 10.1016/0002-9343(93)90350-X · DOI · Paper page
  23. Heaney, 1976, Etidronate disodium in postmenopausal osteoporosis, Clinical Pharmacology and Therapeutics, 20, 593, 10.1002/cpt1976205593 · DOI
  24. Heath, 2000, The effects of cyclical etidronate on early postmenopausal bone loss: an open, randomized controlled study, Journal of Clinical Densitometry, 3, 27, 10.1385/JCD:3:1:027 · DOI
  25. Hesch, 1988, Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38)hPTH and diphosphonate EHDP. Protocol of study 1. osteoporosis trial Hannover, Klinische Wochenschrift, 66, 976, 10.1007/BF01738113 · DOI
  26. Hodsman, 1996, Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis [Review] [34 refs], CMAJ: Canadian Medical Association Journal, 155, 945
  27. Hyldstrup, 2001, Response of cortical bone to antiresorptive treatment, Calcified Tissue International, 68, 135, 10.1007/s002230001204 · DOI
  28. Iwamoto, 2001, Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate, Journal of Orthopaedic Science, 6 (6), 487, 10.1007/s007760100002 · DOI
  29. Iwamoto, 2002, Beneficial effect of etidronate on bone loss after cessation of exercise in postmenopausal osteoporotic women, American Journal of Physical Medicine & Rehabilitation, 81, 452, 10.1097/00002060-200206000-00010 · DOI
  30. Iwamoto, 2003, Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis, Keio Journal of Medicine, 52, 113, 10.2302/kjm.52.113 · DOI
  31. Iwamoto, 2003, Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis, Journal of Orthopaedic Science, 8, 532, 10.1007/s00776-003-0655-5 · DOI
  32. Jowsey, 1971, The treatment of osteoporosis with disodium ethane-1,1-diphosphonate, Journal of Laboratory and Clinical Medicine, 78, 574
  33. Mallette, 1989, Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate, Journal of Bone and Mineral Research, 4, 143, 10.1002/jbmr.5650040203 · DOI
  34. Masud, 1998, Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women, Annals of the Rheumatic Diseases, 57, 346, 10.1136/ard.57.6.346 · DOI
  35. Miller, 1997, Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment [erratum appears in Am J Med 1998 Jun;104(6):608], American Journal of Medicine, 103, 468, 10.1016/S0002-9343(97)00278-7 · DOI
  36. Miller, 1999, A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group, American Journal of Medicine, 106, 513, 10.1016/S0002-9343(99)00062-5 · DOI
  37. Morishige, 2003, Etidronate and hormone replacement therapy (HRT) for postmenopausal women with osteoporosis despite HRT, Archives of Gynecology & Obstetrics, 268, 105, 10.1007/s00404-002-0340-5 · DOI
  38. Orme, 1994, Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation, Clinical Endocrinology, 41, 245, 10.1111/j.1365-2265.1994.tb02537.x · DOI
  39. Ott, 1994, Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis, Journal of Clinical Endocrinology and Metabolism, 78, 968
  40. Ryan, 1994, Clinical experience with etidronate in osteoporosis, Clinical Rheumatology, 13, 455, 10.1007/BF02242942 · DOI
  41. Smith, 1989, Effect of etidronate disodium on bone turnover following surgical menopause, Calcified Tissue International, 44, 74, 10.1007/BF02556464 · DOI
  42. Steiniche, 1991, The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime, Bone, 12, 155, 10.1016/8756-3282(91)90038-K · DOI
  43. Storm, 1996, Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis, Journal of Rheumatology, 23, 1560
  44. Terranova, 1999, [Treatment of postmenopausal osteoporosis with etidronate] [Italian], Minerva Medica, 90, 85
  45. Wimalawansa, 1995, Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study, American Journal of Medicine, 99, 36, 10.1016/S0002-9343(99)80102-8 · DOI
  46. Black D Use of T-Scores to establish comparable diagnostic categories for bone densitiometers [abstract] NIH Consensus Development Conference on Osteoporosis Prevention, Diagnosis and Therapy Bethesda (MD)
  47. Black, 2000, Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group, Journal of Clinical Endocrinology and Metabolism, 85, 4118, 10.1210/jcem.85.11.6953 · DOI · Paper page
  48. Black, 2001, An assessment tool for predicting fracture risk in postmenopausal women, Osteoporosis International, 12, 519, 10.1007/s001980170072 · DOI · Paper page
  49. Brown, 2002, 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada, CMAJ, 167, 1
  50. Browner, 1996, Mortality following fractures in older women. The study of osteoporotic fractures, Archives of Internal Medicine, 156, 1521, 10.1001/archinte.1996.00440130053006 · DOI · Paper page
  51. Health Canada, 2005, Canadian Adverse drug Reaction Monitoring Program. Etidronate
  52. Cardona, 1997, Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials, Osteoporosis International, 7, 165, 10.1007/BF01622285 · DOI · Paper page
  53. Cauley, 2000, Risk of mortality following clinical fractures, Osteoporosis International, 11, 556, 10.1007/s001980070075 · DOI · Paper page
  54. Cooper, 1993, Population-based study of survival after osteoporotic fractures, American Journal of Epidemiology, 137, 1001, 10.1093/oxfordjournals.aje.a116756 · DOI · Paper page
  55. Cranney, 2001, A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis, Osteoporosis International, 12, 140, 10.1007/s001980170147 · DOI
  56. Cranney, 2001, Etidronate for treating and preventing postmenopausal osteoporosis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003376 · DOI
  57. Cummings, 1989, Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women, Archives of Internal Medicine, 149, 2445, 10.1001/archinte.1989.00390110045010 · DOI · Paper page
  58. Dickersin, 1994, Identifying relevant studies for systematic reviews, BMJ, 309, 1286, 10.1136/bmj.309.6964.1286 · DOI · Paper page
  59. Doherty, 2001, Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women, Osteoporosis International, 12, 16, 10.1007/s001980170152 · DOI
  60. Ettinger, 1992, Contribution of vertebral deformities to chronic back pain and disability. The Study of Osteoporotic Fractures Research Group, Journal of Bone and Mineral Research, 7, 449, 10.1002/jbmr.5650070413 · DOI · Paper page
  61. Fleisch, 1997, Bisphosphonates: preclinical aspects and use in osteoporosis, Annals of Medicine, 29, 55, 10.3109/07853899708998743 · DOI
  62. Fleiss, 1993, The statistical basis of meta-analysis, Statistical Methods in Medical Research, 2, 121, 10.1177/096228029300200202 · DOI · Paper page
  63. Hanley, 2003, Osteoporosis, 637
  64. Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd
  65. Hodsman, 2002, Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date, CMAJ, 166, 1426
  66. Kanis, 1994, The diagnosis of osteoporosis, Journal of Bone and Mineral Research, 9, 1137, 10.1002/jbmr.5650090802 · DOI · Paper page
  67. Kherani, 2002, Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review, Drug Safety, 25, 781, 10.2165/00002018-200225110-00003 · DOI
  68. Lindsay, 2001, Risk of new vertebral fracture in the year following a fracture, JAMA, 285, 320, 10.1001/jama.285.3.320 · DOI · Paper page
  69. Alendronate and vertebral fracture risk [multiple letters] Mayo Clinical Proceedings 2005 1233 41
  70. Melton, 1989, Epidemiology of vertebral fractures in women, American Journal of Epidemiology, 129, 1000, 10.1093/oxfordjournals.aje.a115204 · DOI · Paper page
  71. Okeksik, 1999, The impact of incident vertebral fractures on health-related quality of life in women with prevalent fractures [abstract], Journal of Bone and Mineral Research, 14, 262
  72. Ross, 1994, Pain and disability associated with new vertebral fractures and other spinal conditions, Journal of Clinical Epidemiology, 47, 231, 10.1016/0895-4356(94)90004-3 · DOI
  73. Silverman, 1999, The impact of incident vertebral fractures on health-related quality of life in women with prevalent fractures [abstract], Journal of Bone and Mineral Research, 14, 159
  74. Tugwell, 2004, Evidence-based Rheumatology
  75. 1994, Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO study group, World Health Organization Technical Report Series, 843, 1

Cited by

Metadata

Authors
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2008-01-23
Issue
1
Pages
CD003376-CD003376
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
DOI
10.1002/14651858.cd003376.pub3
OpenAlex
W2120433336
Cited by
499
References
12
FWCI
42.38
Type
journal article
Language
en
Update notices
new_version (2024-04-09)
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.